Al's Comment:

I am genuinely thrilled by these findings. The study shows that Vorasidenib has more than doubled the median progression-free survival time from 11 months to 27 months. Moreover, more than half of the patients are still alive, indicating that the median survival has not been reached yet. It's important to note that this study was focused on patients with grade 2 IDH mutant glioma.

 

Vorasidenib is a targeted drug, designed to work specifically on patients with a mutation in either IDH1 or IDH2. With the new nomenclature of brain tumors, it's crucial to understand that Glioblastomas cannot have this mutation. If they do, they are classified under a different name and can no longer be referred to as Glioblastoma. However, some older centers might still use the old naming system, so it's important to check your pathology report and look for IDH1 or IDH mutant.

 

If your report states "IDH wildtype," it means that you do not have the mutation. If you do have the mutation, I would strongly urge you to discuss this drug with your doctor. It's critical not to assume that your doctors will retroactively go through all their old pathology reports to identify patients who could benefit from this drug. Although most probably will, your life is at stake, so it's worth taking the initiative to check the report yourself. If your tumor was not tested for the IDH mutation, I recommend requesting that they perform this test. Your health and well-being are paramount, and this could be a significant step in your treatment journey.

 

Vorasidenib first 'game changer' in 20 years for patients with IDH-mutant grade 2 glioma